Non-Deletional HbH Disease: Next-Step Management When Splenectomy Has Not Achieved the Target Haemoglobin Rise
Clinical Scenario
This protocol is for patients with non-deletional Haemoglobin H (HbH) disease — defined by the presence of a non-deletional α-globin gene mutation (--/αTα). Clinical phenotypes in this subgroup are diverse, and disease expression is generally more severe than in the deletional forms of HbH disease.
Previous Treatment — Insufficient Response
This is a next-line protocol for patients who have already undergone splenectomy (in selected patients older than 5 years) and did not achieve the intended increase in haemoglobin level of 10–30 g/L. This structured protocol represents the management step taken following that inadequate response.
Management Direction
The approach involves a targeted form of iron chelation therapy, initiated when measured iron burden crosses defined thresholds. Clinical success is assessed against specific liver iron concentration and serum ferritin goals. The choice of agent, monitoring framework, and complete decision criteria are detailed in the full structured protocol.
References
- Clinical phenotypes are diverse among affected individuals with non-deletional haemoglobin H (HbH) disease (--/αTα).
- Clinical symptoms of non-deletional HbH are generally more severe than those of deletional forms.
- Iron chelation should be started if LIC >5 mg/g dry weight or ferritin >500 ng/mL.
- Deferasirox doses in the range of 10 to 15 mg/kg/day have been suggested for NTDT.
- Basically, chelation should be started when the LIC is greater than 5 mg/g DW or the serum ferritin is greater than 500 ng/mL with a goal of keeping the LIC between 2 to 5 mg/g DW or the ferritin between 300 and 800 ng/mL.
View source ↗